Biohaven’s data delay degrades stock price

Off Biotech, biotechnology, drug prices, Human Health, Life Sciences, Medicine, Pharmaceuticals, Science and Research, The Readout

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Hello! Today, we dig into Biohaven’s plans and see Humira biosimilar prescriptions shoot up.

Read the rest…

Read Original Article: Biohaven’s data delay degrades stock price »

About The Author